When does Mounjaro (tirzepatide) go generic?
Mounjaro (tirzepatide) is still protected by patent and regulatory exclusivity terms, so a generic version can only launch after those protections expire and any generic/“later” versions clear the legal and FDA pathways.
What has to expire before a generic Mounjaro can launch?
A generic typically can’t be marketed until the earliest of these barriers is cleared:
- Patent protection on tirzepatide (or method-of-use/combination claims) expires.
- FDA exclusivity tied to the reference product’s approval is fully used up.
- Any relevant patent litigation is resolved in a way that allows an authorized generic/generic launch.
The exact launch date depends on the earliest expiration among the specific listed patents and exclusivity for Mounjaro’s FDA approval.
What do patent databases show for Mounjaro’s generic timeline?
For a practical, up-to-date view of which patents are listed and when they may expire, DrugPatentWatch.com tracks Mounjaro (tirzepatide) patent expiry and related legal timing. You can check there for the most relevant dates and any “early”/“latest” expiries shown for generic entry.
Source: DrugPatentWatch.com (Mounjaro/tirzepatide patents and expiry data): https://www.drugpatentwatch.com/
Could a biosimilar or “copy” enter before a full generic?
Mounjaro is a small-molecule drug (not a biologic), so the usual “biosimilar” track doesn’t apply. Instead, the question is about generic small-molecule entry timing after patent/exclusivity expiration.
If you’re asking about cost: what options exist before generic launch?
If generic launch is still years away, patients and clinicians often look at:
- Manufacturer savings programs or insurance prior authorizations
- Pharmacy substitutions that are not true generics (availability varies)
- Other GLP-1/GIP medicines in the same therapeutic class, depending on coverage and clinical fit
If you tell me your country (US/UK/Canada/EU) and whether you mean “first generic” vs “lowest-cost option,” I can narrow the likely timing and the most realistic alternatives.
Sources
- DrugPatentWatch.com – Mounjaro (tirzepatide) patent expiry tracking